The buildout is driven by GLP-1 agonist commercial demand, which has created persistent API supply constraints, and by a broadening clinical pipeline that includes GLP-1 combinations, cyclic peptides, peptide-drug conjugates, and peptide-oligonucleotide hybrids
Short-Term High-Altitude Exposure (3600 m) Alters the type distribution of sperm deformity
Mild GI symptoms are common with weight loss drugs but typically ease as your body gets used to the medication
Infectious bovine viral diarrhea virus (strain NADL) RNA from stable cDNA clones: a cellular insert determines NS3 production and viral cytopathogenicity
Ozempic (a brand name for semaglutide) and similar drugs are all over the news
The natural history of NAFLD spans decades, so longer-term studies are needed to confirm whether GLP-1 agonists can prevent progression to advanced fibrosis, cirrhosis, or hepatocellular carcinoma